EVOLUTION AT MERCK - INVENTING FOR LIFE
MULTIPLE PROGRAMS TARGETING A MARKET OF
OVER $10B GLOBALLY
RSV
.
Most common respiratory pathogen in infants with >50,000 hospitalizations each
year in the U.S. alone and >3 million hospitalizations globally
RSV infection occurs in up to 10% of adults 65 and over in the U.S. each year,
resulting in >175,000 hospitalizations
Total RSV market estimated to be >$5 billion
•
.
CMV
.
Dengue
#1 non-genetic cause of hearing loss in infants in the U.S.
0.3-2.0% global prevalence of congenital cytomegalovirus
>$3 billion market size expected globally
.
V160 has potential to be first in class
•
400 million dengue infections annually with 4 billion patients at risk worldwide
>$3 billion market size across travel and endemic segments
V181 data suggests potential for all 4 dengue serotypes to be covered by 1 dose
CMV=Cytomegalovirus; RSV-Respiratory syncytial virus
MERCK
#
Mike Nally
INVENTING FOR LIFE
66View entire presentation